A natural history study is a type of observational research that tracks how a disease develops and progresses over time, without testing any new treatment. Researchers follow patients, sometimes for years, to document the full arc of a condition: how it begins, what symptoms appear, how quickly it worsens, and what outcomes patients experience. These studies are especially critical in rare diseases, where basic information about how a condition behaves is often incomplete or entirely unknown.
How Natural History Studies Work
The traditional definition of a disease’s “natural history” is the course it takes from onset until resolution or death, in the absence of any intervention. In practice, though, most natural history studies include patients who are receiving whatever standard treatments are currently available. The goal isn’t to withhold care. It’s to build a detailed picture of how the disease behaves in real-world conditions.
These studies are preplanned and structured, not casual data collection. Researchers design them to capture specific variables: demographics, genetic factors, environmental exposures, treatment patterns, and measurable markers of disease progression. Patients may undergo regular assessments, lab work, imaging, or functional tests at scheduled intervals so researchers can quantify how the disease changes over time. This data helps identify which patients progress faster, which symptoms appear first, and what predicts better or worse outcomes.
Unlike a clinical trial, no one is randomized to receive a drug or a placebo. There’s no experimental intervention. Researchers observe and record rather than manipulate. The study population also tends to be more diverse than what you’d see in a clinical trial, which typically enrolls a narrow, carefully selected group of patients. Natural history studies cast a wider net, capturing the full range of how a disease presents across different people.
Why They Matter for Rare Diseases
Natural history studies play an outsized role in rare disease research. For common conditions like diabetes or heart disease, decades of accumulated clinical data already describe how the disease typically unfolds. For rare diseases, that baseline knowledge often doesn’t exist. The FDA has issued specific guidance encouraging natural history studies in rare disease drug development, noting that this information “is usually not available or is incomplete for most rare diseases.”
This gap creates a practical problem. If you’re developing a treatment for a condition that affects only a few thousand people worldwide, you need to know what the disease looks like without treatment before you can prove your drug improves it. Natural history data establishes that baseline. It tells researchers what to measure in a clinical trial, how fast the disease progresses on its own, and what a meaningful improvement would actually look like.
Small patient populations create another challenge: there may not be enough people to run a traditional clinical trial with both a treatment group and a placebo group. In some cases, assigning patients with a life-threatening rare disease to a placebo arm would be unethical. Natural history studies offer a workaround. Patients who were previously documented in a natural history study can serve as a historical comparison group, letting researchers evaluate a new treatment against the known disease trajectory rather than requiring a concurrent placebo arm.
How They Differ From Clinical Trials
The core difference is intent. A clinical trial tests whether a specific intervention works. A natural history study describes what happens without one. Clinical trials take place in controlled, experimental settings with fixed treatment protocols, while natural history studies reflect real-world conditions where patients see different doctors, receive variable treatments, and live with the full complexity of their disease.
Clinical trials enroll homogeneous groups of patients who meet strict criteria. Natural history studies typically include a more heterogeneous population, which makes the data more representative of the broader patient community but also introduces more variability. This tradeoff matters when natural history data is later used as an external comparison for a clinical trial. Differences in how patients were selected, how data was collected, or how outcomes were measured can introduce bias that regulators scrutinize carefully.
The Connection to Patient Registries
You’ll sometimes see natural history studies mentioned alongside patient registries, and they do overlap. There are generally two types of registries. A contact registry connects patients with researchers and clinical trial opportunities. A natural history study registry goes further, systematically collecting clinical and patient-reported data about a disease that can inform every stage of drug development.
These registries serve a dual purpose. They generate the scientific data researchers need, and they build an organized, engaged patient community that regulators value during the drug approval process. Once a treatment is approved, an established natural history registry can also track the safety and effectiveness of that treatment in real-world use, providing ongoing data that complements what was learned in clinical trials.
What They Contribute to Drug Development
Natural history data feeds into drug development at multiple stages. Early on, it helps researchers understand which aspects of a disease are most important to target and which measurements best capture whether a patient is getting better or worse. A natural history study can validate a clinical outcome assessment, essentially proving that a particular test or scale reliably tracks disease progression before it’s used as the primary measure in a drug trial.
Later, this data helps contextualize clinical trial results. If a trial shows that patients on a new drug declined 40% slower than expected, the “expected” part comes from natural history data. Regulators can compare the treatment group’s outcomes against the documented natural course of the disease to determine whether the drug is genuinely effective. This is particularly valuable when the disease is so rare that a large, randomized, placebo-controlled trial isn’t feasible.
The FDA specifically recognizes natural history studies as a tool for supporting regulatory submissions, and has published draft guidance to help researchers design studies that will meet the agency’s standards for use in drug approval decisions.
Participation From the Patient’s Perspective
Enrolling in a natural history study is different from joining a clinical trial. You won’t receive an experimental treatment, which can be frustrating for patients who are hoping for access to something new. The value of participation is indirect: your data helps build the foundation for future treatments, and in some cases, being part of a natural history registry makes it easier to learn about and connect with clinical trials when they do become available.
The burden of participation varies. Some studies require regular clinic visits, blood draws, imaging, or completing detailed questionnaires over months or years. Researchers in the rare disease community have increasingly recognized that this burden matters. Patient advocates have pushed study designers to consider the time, financial cost, anxiety, and logistical effort involved, and to find ways to reduce those demands. The practical impact of study design on patients’ daily lives is now a recognized part of ethical research planning, alongside traditional concerns like informed consent and independent review.
For patients with rare diseases who have few treatment options, the decision to participate carries particular weight. The risk-benefit calculation looks different when there’s no alternative therapy available, and study designers are encouraged to factor in patients’ perspectives from the earliest stages of planning.